Home › NDC Lookup › Ingredients › Docusate Sodium › 00904-6920-93
Docusate Mini Enema docusate sodium 283 mg/5mL Liquid — NDC 00904-6920-93 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Docusate Mini Enema docusate sodium 283 mg/5mL Liquid — NDC 0904-6920-93 (Billing 00904-6920-93)

by Major Pharmaceuticals · 30 TUBE in 1 JAR / 5 mL in 1 TUBE

This is a package of Docusate Mini Enema docusate sodium 283 mg/5mL Liquid from Major Pharmaceuticals, marketed since Aug 2019 and currently FDA-listed; retail pharmacies pay about $0.4612 per mL (NADAC). It is this product's only package size.

NDC 00904-6920-93
🏷️ FDA NDC (as labeled) 0904-6920-93 billing pads the labeler segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0904-6920-93 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0904 labeler · 6920 product · 93 package
Package marketed since
Aug 26, 2019
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0904692093 9
Medicaid fills, this package
2,688 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0904-6920-93
Product NDC 0904-6920
11-digit billing NDC 00904692093
NCPDP billing unit ML — per mL (volume)
RxCUI 1190184
UNII F05Q2T2JA0
Application # M007
SPL Set ID 91099e15-94d7-b684-e053-2a95a90a574e
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-08-26
Route RECTAL
Dosage form LIQUID
Substance DOCUSATE SODIUM

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 46500010305110
GPI class Docusate Mini
GCN Seq No 068187
GCN 30916
HICL code 001326
Ingredient (HICL) Docusate Sodium
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q3
Therapeutic class — intermediate (HIC2) Anal-Rectal Preparations
HIC3 code Q3S
Therapeutic class — specific (HIC3) Laxatives, Local/Rectal
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name DOCUSATE SODIUM MINI ENEMA
FDB brand name Docusate Sodium
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 068187
  • GCN: 30916
  • GPI-14 (Medi-Span): 46500010305110
  • HICL (First Databank): 001326
  • AHFS class code: 56:12.00.00
  • RxCUI (RxNorm): 1190184
Why two NDCs? The FDA registers this code as 0904-6920-93 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00904-6920-93. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Softeners, emollients class.

Drug family (ATC) Softeners, emollients
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name DOCUSATE SODIUM MINI ENEMA Ingredient Docusate Sodium
🧪 What is this product?

This is an over-the-counter rectal liquid enema containing docusate sodium, a stool softener. Docusate sodium is typically used to soften stool and promote bowel movements in people experiencing constipation or difficulty with bowel regularity. The product is marketed as an OTC monograph drug, meaning it follows FDA's established safety and use guidelines for this category of laxative products. The 283 mg dose in a 5 mL liquid formulation is designed for rectal administration.

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.461 $69.18 / 150 ml
Medicaid paysCMS SDUD · 12 mo $0.4551 $68.27 / 150 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 May 2026 Jul 2026 Sep 2026 $0.475 $0.424
▼ Down 3% over the last 7 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00904-6920-93 You're viewing this Main listing 30 TUBE in 1 JAR / 5 mL in 1 TUBE 2019-08-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Enemeez 283 mg/5mL 17433-9876-03 Quest 30 tubes $0.366 — Availability likely save 21%
Docusate Mini Enema 283 mg/5mLthis 00904-6920-93 Major 30 tubes $0.461 — Availability likely —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Aug 2019
📍
2026
Currently FDA-listed
7 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 5655G9Y8AQ
    A synthetic liquid polymer used as a solvent and humectant in medications. It helps dissolve active ingredients, maintain moisture in the formulation, and improve how the medicine flows and is absorbed.

2 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesGlycerin USP and Polyethylene Glycol

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMajor Pharmaceuticals
FDA applicationM007 (OTC MONOGRAPH DRUG)
Labeler code00904
First marketedAug 2019
Product typeHuman Otc Drug
Portfolio630 products on file

More NDCs from Major Pharmaceuticals labeler code 00904

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor or Pharmacist Before Use If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 19 words ▾

Uses For relief of occasional constipation (irregularity). This product generally produces a bowel movement in 2 to 15 minutes.

⏱️ Dosage and Administration 173 words ▾

Directions Adults and children 12 years of age and older (with adult supervision) one to three units daily. Children under 12 years of age, consult a doctor prior to use. Twist off and remove tip.

Lubricate tip prior to insertion: Place a few drops of the tube's liquid content on the shaft prior to insertion. Also apply liquid content or lubricant to the anus before inserting the mini-enema. Positioning: For best results, lay on the left side with knees bent.

Insert slowley into rectum, up to shoulder of tube. Alternate Positions: Administer while seated on the toilet. Or, kneel, then lower head and chest forward until side of face is resting on the surface.

With steady pressure, gently insert the tube into the rectum with care to prevent damage to the rectal wall. Squeeze to empty the contents. Keep the tube squeezed until it is removed from the rectum.

After the contents have been emptied, remove the disposable tube and discard. A small amount of liquid may remain in the unit after use.

⚠️ Warnings 25 words ▾

Warnings For rectal use only. Drug Interaction Precaution: Do not take this product if you are presently taking mineral oil, unless directed by a doctor.

🧪 Active Ingredient 11 words ▾

Drug Facts Active Ingredient (per delivered-dose) Docusate Sodium USP 283 mg

🧪 Inactive Ingredients 7 words ▾

Inactive Ingredients Glycerin USP and Polyethylene Glycol

🎯 Purpose 4 words ▾

Purpose Stool Softener Laxative

📄 Do Not Use 27 words ▾

Do not use Laxative products when abdominal pain, nausea or vomiting are present. Laxative products for a period longer than 1 week unless directed by a doctor.

📄 Ask a Doctor or Pharmacist Before Use If 39 words ▾

Stop use and ask a doctor if you: Rectal bleeding. Noticed a sudden change in bowel habits that persists over a period of 2 weeks. Failed to have a bowel movement after use. This may indicate a serious condition.

🤰 If Pregnant or Breast-Feeding 10 words ▾

Pregnant or Lactating Women Ask a healthcare professional before use.

📄 Keep Out of Reach of Children 21 words ▾

Keep out of reach of children In case of accidental ingestion, get medical help or contact a Poison Control Center immediately.

📄 Other Information 18 words ▾

Other Information Other Information Store at room temperature 15°-30° C (59°-86° F) RETAIN BOTTLE FOR COMPLETE DRUG FACTS

📄 Questions or Comments 5 words ▾

Questions or Comments: (800) 616-2471

📄 Package Label / Principal Display Panel 1 words ▾

pdp

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.7K
Units reimbursed last 4 qtrs
412.8K
Gross reimbursed last 4 qtrs
$187.9K
Avg / prescription
$69.89
Avg / unit
$0.4551
Latest quarter Q1 2026
629Rx
Medicaid pays / mL
$0.4551
gross reimbursed
vs
NADAC / mL
$0.4612
acquisition cost
=
Spread
−$0.0061
-1% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
50% FFS 50% MCO
Fee-for-service · 1,350 Rx Managed care · 1,338 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 88,085 units · 1,535 per 100k residents MN Wisconsin: 9,795 units · 166 per 100k residents WI Michigan: 43,270 units · 431 per 100k residents MI New York: 48,902 units · 250 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 43,661 units · 370 per 100k residents OH Pennsylvania: 13,550 units · 105 per 100k residents PA New Jersey: 6,390 units · 68.8 per 100k residents NJ Massachusetts: 18,225 units · 260 per 100k residents MA California: no data reported CA Utah: 2,400 units · 70.2 per 100k residents UT Colorado: no data reported CO Nebraska: 18,795 units · 950 per 100k residents NE Missouri: 9,600 units · 155 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 4,160 units · 47.7 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 12,170 units · 164 per 100k residents AZ New Mexico: no data reported NM Kansas: 2,100 units · 71.4 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: 11,950 units · 222 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 79,738 units · 261 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
47.71,535
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Minnesota 1,535 /100k
2 Nebraska 950 /100k
3 Michigan 431 /100k
4 Ohio 370 /100k
5 Texas 261 /100k
6 Massachusetts 260 /100k
7 New York 250 /100k
8 South Carolina 222 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Docusate Mini Enema (this brand).

Top reported reactions

Nausea1,622
Fatigue1,591
Dyspnoea1,398
Constipation1,225
Diarrhoea1,225
Vomiting1,191
Pain1,170

Reporter sex

20,328 reports
Male · 43%
Female · 56%
Unknown · 0%

Serious outcomes

Hospitalization9,623
Death2,788
Disabling800
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,736 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00904-6917-61 · Major 00904-6923-61 · Major →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.